Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 for active systemic lupus erythematosus
CTR20242914Phase 2Active
- Sponsor
- ImmunoCare
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMC-002 in systemic lupus erythematosus (SLE), sponsored by ImmunoCare. Started Oct 2024; status: active.
02
Drugs
IMC-002
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20242914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242914.